Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ibrutinib + obinutuzumab in previously untreated high-tumor-burden follicular lymphoma
2014-005164-15Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Sep 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and obinutuzumab in follicular lymphoma (FL), sponsored by LMU Klinikum. Primary endpoint: One-year progression-free survival rate. Started Sep 2015; status: completed.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2014-005164-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005164-15.